Just in Time for the Holidays: FDA’s Updated Guidance on CBD Amid More Warning Letters

FDA Update Despite the impending Thanksgiving holiday, the U.S. Food and Drug Administration (“FDA”) kept plenty busy this week in keeping the hemp industry on its toes issuing: (a) yet another round of a whopping fifteen (15) warning letters to companies purportedly marketing “unapproved new drugs” containing hemp-derived cannabidiol (“CBD”) in violation of FDA regulations;

By |2019-12-06T09:08:12-07:00December 5th, 2019|HLG Blogs|

Will Congress Provide Direction to FDA?

Earlier this week, as part of the Senate Appropriations Agriculture Subcommittee meeting, Senator Mitch McConnell (KY) submitted language concerning hemp-derived products and the FDA’s lingering uncertainty concerning the same as a potential proposal to be included as part of forthcoming budgetary legislation. The forthcoming proposed budget provides $2 million to the FDA for research, policy

By |2019-09-20T11:47:25-06:00September 20th, 2019|Hemp, HLG Blogs, Our Voice|